MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Not yet recruiting · NCT06549751 · Registry updated 2026-05-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Not yet recruiting | Phase 1 | 2026-05-13 | NCT06549751 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| M.D. Anderson Cancer Center | 1145 |
| Marker Therapeutics, Inc. | 3 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The University of Texas MD Anderson | Houston | United States | 1 |